CTOs on the Move

IMIDomics

www.imidomics.com

 
IMIDomics is a biotechnology company focused on Patient-Centric drug discovery for immune-mediated inflammatory diseases (IMIDs). Our goal is to discover new and impactful IMID drugs by focusing on carefully selected patients, and stratifying populations to identify those most likely to respond. IMIDomics is powered by a unique Clinical Discovery EngineTM, which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d`Hebron Institute of Research, to establish a deeper understanding of IMID diseases. By doing so, IMIDomics has identified previously unrecognized targets, six of which have been selected for development. By relying on access ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Eric Perakslis
Senior Vice President and Chief Technology Officer Profile

Similar Companies

One Tast

One Tast is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nutripro Biosystems

Nutripro Biosystems is a Worthington, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

San Miguel Technology

San Miguel Technology Llc is a Landenberg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PepGen

Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders.

Insmed

Insmed is a global biopharmaceutical company focused on the needs of patients with rare diseases. Headquartered in Bridgewater, NJ, Insmed is a dynamic and rapidly growing company with a strong pipeline of drug candidates. At Insmed, we are on a mission to transform the lives of patients battling serious rare diseases. We are developing novel, targeted therapies to help serve the critical unmet needs of these patients. In concert with developing therapeutic solutions, we are committed to improving the entire patient experience. “Insmed is a team of talented and motivated professionals who are dedicated to making a difference in the lives of patients with rare diseases, said Will Lewis, president and CEO at Insmed.